<DOC>
	<DOCNO>NCT00578565</DOCNO>
	<brief_summary>This study examine course patient progressive rheumatoid arthritis associate interstitial lung disease ( RA-ILD ) treat rituximab safety progression-free survival 48 week . Safety rituximab therapy disease assess patient history , physical exam laboratory parameter . - Twelve male/or female patient RA-associated lung disease ( 6 nonspecific interstitial pneumonia ( NSIP ) usual interstitial pneumonia ( UIP ) histological subtype ) enrol - The study involve 12 visit 48 week - Rituximab administer intravenously Day 1 Day 15 repeat dose six month .</brief_summary>
	<brief_title>Rituximab Rheumatoid Arthritis Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Diagnosis RA accord revised 1987 American Rheumatism Association criteria 2 . Absence clinical feature suggest infection , neoplasm , sarcoidosis , interstitial lung disease UIP NSIP , collagen vascular disease , exposure know fibrogenic drug environmental factor 3 . Diagnosis progressive interstitial pneumonia UIP NSIP subtype , base follow criterion 1 . Clinical symptom consistent interstitial lung disease onset 3 month 36 month prior screen . 2 . Worsening demonstrate one follow within past year : &gt; 10 % decrease Forced Vital Capacity ( FVC ) increase infiltrates chest Xray High Resolution Computed Tomography ( HRCT ) , worsen dyspnea rest exertion 3 . Diagnosis UIP NSIP either follow : Open videoassisted thoracic surgery ( VATS ) lung biopsy show definite probable UIP NSIP HRCT scan show definite probable UIP NSIP AND abnormal pulmonary function test ( reduce FVC decrease diffuse capacity carbon monoxide ( DLco ) impair gas exchange rest exercise ) AND insidious onset otherwise unexplained dyspnea exertion bibasilar , inspiratory crackle auscultation 4 . FVC &gt; 50 % predict value Screening 5 . DLco &gt; 30 % predict value Screening 5 . No change diseasemodifying antirheumatic drug ( DMARD ) treatment within last 3 month 1 . History clinically significant environmental drug exposure know cause pulmonary fibrosis . 2 . Forced expiratory volume one second ( FEV1 ) FEV1/FVC ratio &lt; 0.6 screening ( pre postbronchodilator ) . 3 . Residual volume &gt; 120 % predict Screening 4 . Evidence active infection 5 . Any pulmonary condition UIP/NSIP , , opinion site principal investigator , likely result death patient within next year 6 . History unstable deteriorate cardiac neurologic disease 7 . Pregnancy lactation 8 . Treatment cyclophosphamide , cyclosporine , interferon gamma beta , antitumor necrosis factor therapy , antiinterleukin 1 ( IL1 ) therapy endothelin receptor blocker within last 8 week ; experimental therapy rheumatoid arthritis 9 . Creatinine &gt; 1.5 X upper limit normal range ( ULN ) Screening 10 . Hematology outside specify limit : white blood cell ( WBC ) &lt; 2,500/mm^3 absolute neutrophil count ( ANC ) &lt; 1500 11 . Hematocrit &lt; 27 % &gt; 59 % , platelet &lt; 100,000/mm^3 screen 12 . Positive hepatitis B C serology 13 . Any medical condition , opinion site principal investigator , may adversely affect participation study 14 . History recurrent significant infection history recurrent bacterial infection 15 . Known active bacterial , viral fungal mycobacterial , infection ( include tuberculosis atypical mycobacterial disease , exclude fungal infection nail bed ) major episode infection require hospitalization treatment i.v . antibiotic within 4 week screen oral antibiotic within 2 week prior screen 16 . Abnormal neurological examination reflective central nervous disease , include paresis , cognitive impairment problem coordination 17 . Current enrollment another clinical trial 18 . Fever ( &gt; 99.5ยบ F ) 19 . History previous rituximab administration 20 . Receipt vaccine , particularly live viral vaccine , within 4 week first study dose 21 . Decreased Immunoglobulin G ( IgG ) Immunoglobulin M ( IgM ) level ( low limit normal range ) 22 . Present past malignancy 23 . History severe allergic anaphylactic reaction administration humanize murine monoclonal antibody 24 . Positive human immunodeficiency virus ( HIV ) serology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Interstitial Pneumonia</keyword>
	<keyword>Rheumatology</keyword>
	<keyword>Rituximab</keyword>
</DOC>